Navigation Links
Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease,Presented at International Congress of Parkinson's Disease and,Movement Disorders

Faust's lead molecule, FP0011, exhibited a differentiated combination of therapeutic effects and good tolerance in mid- to late-stage patients

STRASBOURG, France, June 6, 2007 - Faust Pharmaceuticals S.A., a clinical stage product company specializing in the discovery and development of drugs for diseases of the nervous system, today announced that the Phase IIa clinical trial results of its small molecule glutamate release inhibitor, FP0011, are being presented at the Movement Disorder Society (MDS)'s 11th International Congress of Parkinson's Disease and Movement Disorders, taking place this week in Istanbul, Turkey. The poster, presented by the study's Principal Investigator, Olivier Rascol, M.D., of University Hospital, Toulouse, has been selected for presentation at the Highlights of Posters session during the conference.

In the trial, FP0011 was well tolerated and improved Parkinsonian symptoms as measured by the Unified Parkinson's Disease Rating Scale (UPDRS), as well as motor fluctuations as measured by patient diaries. The compound had positive effects in three critical areas: "core" Parkinsonian motor symptoms (such as tremor, rigidity and akinesia), axial symptoms not sensitive to L-dopa and other commonly-prescribed dopaminergic drugs (such as disturbance of posture, balance and gait), and dyskinesia (i.e. the jerky uncontrolled movements that result as a side effect of long term L-dopa therapy).

The Phase IIa trial was conducted according to an innovative "n of 1" trial design in which a small population (n=8) of mid-to-late stage Parkinsonian patients with L-dopa-induced motor complications were administered FP0011 or placebo over 4 cross-over periods on a randomized, blinded basis.

Professor Rascol, Dr. Joaquim Ferreira (Lisbon), and Dr. Lucette Lacomblez (Paris), were principal investigators in this Phase II trial. The "n of 1" trial design was previously used by Dr. Ferrei ra to confirm that amantadine, originally developed as an antiviral and now commonly used to address side effects of L-dopa therapy, could help Parkinson's patients.

"The differentiated profile observed in this Phase II trial is interesting and intriguing as there are currently no other drugs with this combination of therapeutic effects," said Professor Rascol. "Particularly if the therapeutic effect on non-levodopa sensitive symptoms can be confirmed in the Phase IIb and subsequent trials, the compound would address a very important unmet medical need for all mid-to-late stage patients developing postural disturbances, and could represent a significant advance in approaches to Parkinson's disease."

Also being presented at the conference is a poster on the results of FP0011 in a MPTP macaque monkey model of Parkinson's disease, by Dr. Jonathan Brotchie, CEO of Atuka Ltd. of Toronto, Canada. In this trial, monkeys that have developed dyskinesia from the administration of L-dopa to treat Parkinsonian symptoms from the neurotoxin, MPTP, were administered FP0011. FP0011 reduced the severity of L-dopa-induced dyskinesia while extending the duration of the anti-Parkinsonian action of L-dopa.

"Unlike other drugs on the market that increase the duration of L-dopa action, FP0011 did not exacerbate the problem of dyskinesia," said Dr. Brotchie. "If these effects were seen in patients, then over the course of a day such an action could significantly enhance the quality of life of people with advanced Parkinson's disease."

Commenting on these presentations, Thomas Seoh, CEO of Faust noted that: "These mutually supportive data in the Phase IIa trial and the MPTP monkey trial presented at this conference strongly support the further clinical development of FP0011 as an adjunctive therapy to L-dopa in patients with established motor complications. We look forward to confirming and extending these results in larger trials for Parkinson's patients. Ultima tely, we hope to demonstrate that FP0011 can be a potent, safe glutamate release inhibitor that could have a role in other neurological diseases and conditions where excess glutamate has been implicated, such as Alzheimer's disease, ALS, Huntington's disease, multiple sclerosis and neuropathy."

About Parkinson's disease Parkinson's disease affects both men and women in almost equal numbers with no apparent social, ethnic, economic or geographic links. In the United States, it is estimated that 60,000 new cases are diagnosed each year, joining the 1.5 million Americans who currently have Parkinson's disease. While the condition usually develops after the age of 65, 15% of those diagnosed are under 50. Estimates range up to about 1,200,000 patients in Europe.

About Faust Pharmaceuticals - www.faustpharma.com Faust Pharmaceuticals is a clinical stage products company specializing in the discovery and development of drugs for diseases of the nervous system. The company's lead compound, FP0011, is a small molecule glutamate inhibitor in Phase II for Parkinson's disease and ALS. A second compound, FP0023, is a fetal gene activating utrophin inducer in preparation for Phase I/II for Duchenne Muscular Dystrophy. The company additionally has pre-clinical programs on targets such as mGluR (metabotropic glutamate receptor), as well as a proprietary drug discovery platform targeting GPCRs (G-Protein Coupled Receptors).

For further information, please contact:
Andrew Lloyd & Associates Andrew Lloyd / Neil Hunter Tel: +44 1273 675100 allo@ala.com>allo@ala.com / neil@ala.com>neil@ala.com

Katie Ollerenshaw ANDREW LLOYD & ASSOCIATES http://www.ala.com katie@ala.com

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND Tel: +44 1273 675100 Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01


'"/>




Related medicine technology :

1. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
2. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016   Bernstein Liebhard LLP today announced ... United States District Court for the District of ... consisting of all persons or entities who purchased common shares ... INSY ) from March 3, 2015 through January 25, 2016 ... its officers with violations of the Securities Exchange Act of ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... Summary Breast cancer, a malignant neoplasm, is the ... in women worldwide, accounting for 16% of all female ... women diagnosed with breast cancer has increased over the ... declined due to earlier diagnosis and better treatment options. ... past four decades, especially with increasing usage of targeted ...
Breaking Medicine Technology:
(Date:2/5/2016)... Lake City, UT (PRWEB) , ... February 05, 2016 , ... ... Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist ... Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV ...
(Date:2/5/2016)... , ... February 05, 2016 , ... ... the addition of micro-needling services in their Napa Valley office. The technique utilizes ... Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a ...
(Date:2/5/2016)... ... 05, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Tasting Event at the La Gorce Country Club in Miami Beach on March ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills. It’s ... their New Year’s resolutions to lose weight and get in shape by joining gyms, ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... (APDA) announced the election of Patrick McDermott as Chairman of the National Board of ... welcome Pat as Chairman of the Board,” stated Leslie A. Chambers , APDA ...
Breaking Medicine News(10 mins):